دورية أكاديمية
Real World Outcomes in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Receiving Palliative Intent Therapies.
| العنوان: | Real World Outcomes in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Receiving Palliative Intent Therapies. |
|---|---|
| المؤلفون: | Ayers EC; Division of Hematology-Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA. Electronic address: emily.ayers@pennmedicine.upenn.edu., Margolis D; Department of Biostatistics, Epidemiology and Informatics, Perlman School of Medicine, Philadelphia, PA., Landsburg DJ; Division of Hematology-Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA. |
| المصدر: | Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2020 Oct; Vol. 20 (10), pp. 661-667. Date of Electronic Publication: 2020 May 16. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2011-: [New York] : Elsevier Original Publication: Dallas, Tex. : Cancer Media Group |
| مواضيع طبية MeSH: | Lymphoma, Large B-Cell, Diffuse/*therapy, Adolescent ; Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged ; Recurrence ; Retrospective Studies ; Treatment Outcome ; Young Adult |
| مستخلص: | Background: Outcomes in patients with relapsed/refractory (R/R) diffuse large b-cell lymphoma (DLBCL) who are ineligible for and/or fail high-dose chemotherapy and autologous stem cell transplantation in the second line are poor. There is no preferred palliative-intent treatment for patients in this setting. Patients and Methods: A retrospective cohort study was performed using the nationwide de-identified electronic health record-derived Flatiron Health database. Event-free survival (EFS) and overall survival (OS) was evaluated for patients with R/R DLBCL who were ineligible for and/or failed autologous stem cell transplantation in the second line and received bendamustine, gemcitabine, or lenalidomide. Results: Three hundred eighty-three patients were included. Therapy received was bendamustine in 158 patients, gemcitabine in 142 patients, and lenalidomide in 83 patients. The median EFS and OS for all patients was 4.1 months and 8.7 months, respectively. Compared with patients receiving bendamustine or gemcitabine, those receiving lenalidomide demonstrated significantly longer median EFS (6.8 vs. 3.8 months; P = .006) and median OS (15.4 vs. 7.7 months; P = .045). Survival outcomes were also improved for lenalidomide-treated patients specifically in the second- as well as third- or fourth-line settings. Conclusion: Use of lenalidomide resulted in prolonged EFS and OS as compared with bendamustine or gemcitabine in this cohort of patients with R/R DLBCL receiving palliative therapy. This first large-scale analysis of real-world outcomes for this patient population may guide current clinical management as well as serve as a benchmark for survival outcomes in the standard-of-care setting, which may aid in the design of future clinical trials. (Copyright © 2020 Elsevier Inc. All rights reserved.) |
| References: | Blood. 2017 Oct 19;130(16):1800-1808. (PMID: 28774879) J Clin Oncol. 2007 May 10;25(14):1916-23. (PMID: 17488991) Leukemia. 2013 Sep;27(9):1902-9. (PMID: 23545991) Clin Lymphoma Myeloma Leuk. 2019 Dec;19(12):763-775.e2. (PMID: 31678080) Nat Med. 2015 Aug;21(8):922-6. (PMID: 26193343) Br J Haematol. 2018 Sep;182(5):633-643. (PMID: 29808921) Ann Oncol. 2002 Aug;13(8):1285-9. (PMID: 12181253) J Clin Oncol. 2010 Sep 20;28(27):4184-90. (PMID: 20660832) N Engl J Med. 1995 Dec 7;333(23):1540-5. (PMID: 7477169) N Engl J Med. 2017 Dec 28;377(26):2545-2554. (PMID: 29226764) J Comp Eff Res. 2019 Oct;8(13):1067-1075. (PMID: 31452397) Haematologica. 2016 Jul;101(7):e284-6. (PMID: 27013652) N Engl J Med. 2017 Dec 28;377(26):2531-2544. (PMID: 29226797) Leuk Lymphoma. 2004 Jul;45(7):1391-4. (PMID: 15359638) J Clin Oncol. 2005 Jun 20;23(18):4117-26. (PMID: 15867204) Blood. 2010 Sep 23;116(12):2040-5. (PMID: 20548096) Br J Haematol. 2013 Sep;162(5):639-47. (PMID: 23834234) Bone Marrow Transplant. 2016 Jan;51(1):51-7. (PMID: 26367239) J Clin Oncol. 2013 Jun 10;31(17):2103-9. (PMID: 23650408) Clin Cancer Res. 2017 Aug 1;23(15):4127-4137. (PMID: 28381416) Ann Hematol. 2018 Aug;97(8):1437-1443. (PMID: 29619501) Leuk Lymphoma. 2015 Jun;56(6):1671-6. (PMID: 25241999) J Clin Oncol. 2020 Jan 10;38(2):155-165. (PMID: 31693429) Haematologica. 2013 Nov;98(11):1726-31. (PMID: 23753028) |
| معلومات مُعتمدة: | T32 CA009679 United States CA NCI NIH HHS |
| فهرسة مساهمة: | Keywords: Chemotherapy; Lenalidomide; Non-Hodgkin lymphoma; Non-curative intent therapy; Salvage therapy |
| تواريخ الأحداث: | Date Created: 20200625 Date Completed: 20210901 Latest Revision: 20211002 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC8075299 |
| DOI: | 10.1016/j.clml.2020.05.008 |
| PMID: | 32576502 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 2152-2669 |
|---|---|
| DOI: | 10.1016/j.clml.2020.05.008 |